---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-145656"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:47:11.556197+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AVROBIO Q1 net loss $29.8M, cash runway into Q1 2024; cystinosis trial fully enrolled

## Summary
- Net loss $29.8M in Q1 2022, up from $26.9M in Q1 2021.
- R&D expenses $19.3M; G&A $10.2M including severance costs.
- Cash and equivalents $161.7M as of Mar 31, 2022; runway into Q1 2024.
- Cystinosis Phase 1/2 trial fully enrolled (6 patients); new data at ASGCT.
- Plan to start company-sponsored trials in 2023 for cystinosis, Gaucher type 3, Hunter, Pompe.

## SEC filing metadata
- accession: 0001193125-22-145656
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000119312522145656/0001193125-22-145656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000119312522145656/d356485d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-145656
- JSON: https://secwatch.observer/filing/0001193125-22-145656.json
- Plain text: https://secwatch.observer/filing/0001193125-22-145656.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.